Neuroscientists are closing in on a long elusive goal: pinpointing the exact brain cells that make anxiety surge or suddenly ...

Study finds middle age changes how brains respond to weight loss. Brain inflammation increased during dieting despite ...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer's Patients Treated with Anti-Amyloid ...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial Builds on Recent Evidence of Persistent ...

Tiziana Life Sciences (TLSA) announces that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, ...

A significant, long-term reduction in calorie consumption resulted in a slowing of aging in the brain, according to a study of rhesus monkeys recently published in Aging Cell. The study was conducted ...

First Patient Expected to be Dosed Next Week with Intranasal ForalumabPET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi® (Lecanemab) Anti-Amyloid Therapy BOSTON, ...

ABSTRACT: As a key process in maintaining cellular metabolic homeostasis, the targeted regulation of autophagy offers new insights into the treatment of metabolic disorders such as diabetes, obesity, ...

POTOMAC, MD / ACCESS Newswire / August 5, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging AI to develop innovative treatments ...

I rate INmune Bio, Inc. a speculative Strong Buy for high-risk investors, hinging on XPro's upcoming Phase II results in early Alzheimer's disease. XPro's unique mechanism targets neuroinflammation ...

Microglia are known to play an important role in Alzheimer's disease, but exactly what they do has remained a mystery. Scientists in the Bart De Strooper Lab at the VIB-KU Leuven Center for Brain & ...